September 2010

Overactive Bladder - 2010

Report Authors
Cynthia Mundy, Ph.D.
Kat Lynch, M.P.H.
Donal Minihan, M.V.B., Ph.D.
  • Pages:109
  • Tables:25
  • Figures:6
  • Citations:108
  • Drugs:29
  • Interviews:22


Despite the shortcomings of current therapies—which are only moderately effective and often impose a high side-effect burden—the market for overactive bladder (OAB) drugs has grown significantly and steadily over the last ten or more years. As a result, it is an attractive environment for drug companies, who persevere in the face of recent OAB clinical failures to develop novel therapies that capitalize on physicians’ eagerness for more-effective drugs with novel mechanisms of action.

Questions Answered in This Report:

  *   Thought-leading physicians contend that although OAB is increasingly common with age, a large percentage of those suffering from it are unrecognized and untreated. How will the aging of the populations in the major pharmaceutical markets affect the size of the OAB prevalent population? Which factors impede the identification and treatment of OAB patients? What trends in diagnosis and drug-treatment rates are predicted through 2019?

  *   In their ongoing efforts to establish positions in the OAB market, drug developers have focused on solving two major unmet needs: achieving greater control of symptoms compared with oral anticholinergics and optimizing tolerability to improve compliance. How have the launches of several new anticholinergic brands affected the distribution of major-market sales for agents in this class? How do products’ efficacy and tolerability drive prescribing decisions? Is any anticholinergic poised to unseat ER tolterodine (Pfizer/Almirall’s Detrol-LA/Detrusitol-XL) as the top-selling agent in this class?

  *   Thought-leading physicians tell us they are eager for novel OAB therapies with mechanisms of action that differ from anticholinergics. Which novel noncholinergic agents are expected to launch during the 2009-2019 forecast period? Will these therapies displace or be synergistic with anticholinergics in the OAB treatment algorithm?

  *   Generic erosion is a significant constraint on the future growth of the OAB market. Which products are expected to lose market exclusivity by 2019? How will expensive branded agents fare in the face of generic entrants and biosimilar competitors?


Markets: United States, France, Germany, Italy, Spain, United Kingdom, Japan.

Primary research: 22 country-specific interviews with urologists, urogynecologists, and GP/PCPs.

Epidemiology: Total prevalent cases of OAB; prevalent cases of OAB by symptom, including urinary incontinence, urinary frequency, and nocturia.

Emerging therapies: Phase II: eight drugs; Phase III: two drugs; preregistration: one drug. Coverage of select preclinical and Phase I products.

Market forecast features: Using a proprietary analogue generic erosion model and anticipated launch dates based on primary and secondary research, we forecast drug sales for the treatment of OAB through 2019.

Fill out the form below to contact sales.

Search Reports

Mentioned in this report:

  • - Allergan
  • - Amdipharm
  • - Antares
  • - Apogepha
  • - Astellas Pharma
  • - Bayer
  • - BioXell
  • - Boehringer Ingelheim
  • - Chiesi
  • - Enhance Pharmaceuticals
  • - Eli Lilly
  • - Esteve
  • - FemmePharma
  • - Galen
  • - GlaxoSmithKline
  • - Glenmark
  • - Helsinn
  • - Hisamitsu
  • - Ion Channel Innovations
  • - Janssen-Cilag
  • - Johnson & Johnson
  • - Kissei Pharmaceutical
  • - Kowa Soyaku
  • - Kyorin Pharmaceutical
  • - Kyowa Hakko
  • - LG Life Sciences
  • - Lorex Synthélabo
  • - Madaus
  • - Mallinckrodt
  • - McNeil
  • - Merck
  • - Mt. Cook Biosciences
  • - Novartis
  • - Novo Nordisk
  • - Ono Pharmaceuticals
  • - Organon
  • - Otsuka
  • - Pfizer
  • - Pfleger
  • - Plethora
  • - Roche
  • - Rottapharm
  • - Salvat
  • - Sanofi-Aventis
  • - Taiho
  • - Takeda
  • - Teva
  • - Watson Pharmaceuticals
  • - UCB
  • - Vernalis
Decision Resources Group brands include: